Clinical Trials Logo

Relapsed Small Cell Lung Cancer clinical trials

View clinical trials related to Relapsed Small Cell Lung Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04543916 Withdrawn - Clinical trials for Relapsed Small Cell Lung Cancer

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Start date: June 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-arm, open-label, multicenter phase 1/2 trial designed to establish the recommended phase 2 dose (RP2D) of daily oral venetoclax when given in combination with irinotecan in patients with relapsed or refractory small cell lung cancer (SCLC).